Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.
about
Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritisInterleukin-6: a new therapeutic targetBiologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysisEtanercept for the treatment of rheumatoid arthritisAdverse effects of biologics: a network meta-analysis and Cochrane overviewBiologics for rheumatoid arthritis: an overview of Cochrane reviewsMethotrexate in rheumatoid arthritis: a quarter century of developmentComparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION studyDestructive effects of murine arthritogenic antibodies to type II collagen on cartilage explants in vitro.Gastrin-releasing peptide, substance P and cytokines in rheumatoid arthritisAcute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score.Bone and TNF in rheumatoid arthritis: clinical implicationsRate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databasesMonoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitorsMy treatment approach to rheumatoid arthritisBiologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritisEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateBiologic agents for rheumatoid arthritis--negotiating the NICE technology appraisalsPharmacokinetics, efficacy and safety profiles of etanercept monotherapy in Japanese patients with rheumatoid arthritis: review of seven clinical trialsBiochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities.Combination therapy with biologic agents in rheumatic diseases: current and future prospectsRheumatoid arthritis: identifying and characterising polymorphisms using rat modelsDifferences in reactivation of tuberculosis induced from anti-TNF treatments are based on bioavailability in granulomatous tissueEffect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trialsComparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression AnalysisEstablishment of age- and sex-adjusted reference data for hand bone mass and investigation of hand bone loss in patients with rheumatoid arthritis treated in clinical practice: an observational study from the DANBIO registry and the Copenhagen Osteo[Phase IV non-interventional studies in the treatment of rheumatoid arthritis with biologicals in Germany : real-life clinical practice data].Biological drugs for the treatment of rheumatoid arthritis by the subcutaneous route: interpreting efficacy data to assess statistical equivalence.Presentation and analysis of data on radiographic outcome in clinical trials: experience from the TEMPO study.Presentation and analysis of radiographic data in clinical trials and observational studies.Tapering and discontinuation of methotrexate in patients with RA treated with TNF inhibitors: data from the DREAM registry.Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review.Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety.Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor.Phospholipase C gamma 2 is critical for development of a murine model of inflammatory arthritis by affecting actin dynamics in dendritic cells.Changes in plasma IL-6, plasma VEGF and serum YKL-40 during Treatment with Etanercept and Methotrexate or Etanercept alone in Patients with Active Rheumatoid Arthritis Despite Methotrexate TherapyPromising bone-related therapeutic targets for rheumatoid arthritis.The use of tumour necrosis factor alpha-blockers in daily routine. An Austrian consensus project.Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project.
P2860
Q21134808-25F1BB03-E73E-45D0-8B18-2C5C00EB7C11Q21195659-9C23234D-56E3-448D-8B4C-53B9D328FFC7Q24185797-54EB4E3D-C7D6-4255-86A2-5F6074E7B84EQ24202751-9AA1268F-18BA-4158-806F-5E406F37816BQ24234197-AF158C9A-11AF-4480-8A7D-17A6993132E5Q24240731-C720E1A9-F630-48C1-A7AB-D9368B690D2DQ24597346-1E631D83-0F50-4318-9673-FEBD253046C0Q24630541-FF61C90E-02DB-417E-B8EB-CFB16407BA44Q24812166-0BA8CBBB-0BAB-4B00-AB61-5C7CF9A3D331Q24816927-E7F76BA1-111C-4DD2-A192-8533C79DA5CAQ24817087-63A5E4DA-D362-40DA-B97E-B928A758ECE8Q26777895-1E2B4E85-B00B-4BD0-91C9-70344091FEEFQ26778600-08E74475-4DAA-41B1-8DBC-CB39512FB0BBQ26824970-9031CC23-A314-43FF-BCE9-C7A1255A945DQ26829955-73986C7B-DC0B-4F3B-84F8-D2DA39A2540AQ26852235-731CC708-1080-4F3A-A4AD-5BA63C835DD8Q26859134-A1C156A5-1AC6-4CA8-B707-BF4E3A4C1E69Q27010957-927E4BB5-51E4-4097-83E5-D9C7296E61A4Q27015772-7DDA4627-3AA8-4FBC-A74F-082F5EDC73CCQ27687777-5C1D8329-86EC-4484-AE8E-FE799C50DD92Q28066250-401CAD03-2832-455D-892A-CA073A8534ECQ28073099-7DC4551A-21A9-4BC7-8E14-4117A5F21277Q28469340-4FD58115-3208-4F55-86DB-E391DBE61CA4Q28543128-30FB4988-2CF7-4C81-9341-AA083539BB26Q28547851-8A261368-B3A5-4DFE-9593-F3A1901DAE15Q28603734-58FCD3D2-949C-4AD1-9C5B-B81B72867194Q30699616-35E319AE-DAF7-4AF3-BBA7-DB0F5AE7222FQ30872562-DC7DA5C1-08F6-4821-8F61-0DF6B325276CQ30980061-FBCFAD0B-0862-443E-A39A-ED0C4367B7BFQ31012453-723B72C4-36E9-418D-8B08-B7731BFF4450Q31017424-6C7765B0-F30D-4764-9441-F9FAAE06C6D5Q31021097-B0012825-ADEF-4584-A210-2CD35DABC70FQ33311301-033D0CE4-F393-472C-8009-4356FF89A5A7Q33328963-D092ECE0-67CB-4F95-BFEB-AD18C4FDDBCCQ33400381-EB925F68-6633-407C-AE68-C4C357B0091DQ33527426-17A4D52B-7DFD-4D1D-B084-5ACF86A063C4Q33552038-B95961A7-34E8-4CD8-8050-5C9DAFB93099Q33554023-1CDA3F3B-1994-4D2D-874F-1112057CCACDQ33554356-7CDAA939-3F51-4445-A8A2-0641C8DCC468Q33573112-F504C12A-07ED-48F7-AD16-E238E4262A2F
P2860
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
name
Therapeutic effect of the comb ...... d randomised controlled trial.
@ast
Therapeutic effect of the comb ...... d randomised controlled trial.
@en
type
label
Therapeutic effect of the comb ...... d randomised controlled trial.
@ast
Therapeutic effect of the comb ...... d randomised controlled trial.
@en
prefLabel
Therapeutic effect of the comb ...... d randomised controlled trial.
@ast
Therapeutic effect of the comb ...... d randomised controlled trial.
@en
P2093
P50
P1433
P1476
Therapeutic effect of the comb ...... d randomised controlled trial.
@en
P2093
Andrew Gough
Emilio Martín Mola
Jacques Sany
Joachim Kalden
Joseph Wajdula
Julien P de Jager
Lucas Settas
Marie Sanda
Michel Malaise
Ronald Pedersen
P304
P356
10.1016/S0140-6736(04)15640-7
P407
P577
2004-02-01T00:00:00Z